We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MERCK RECEIVES SIX MONTHS ADDITIONAL EXCLUSIVITY ON VIOXX
MERCK RECEIVES SIX MONTHS ADDITIONAL EXCLUSIVITY ON VIOXX
February 27, 2004
The FDA has granted Merck an extra six months of marketing exclusivity for its pain drug Vioxx (rofecoxib), the firm said Friday.